Drug agency Dr Reddy’s Laboratories Ltd on Wednesday (February 18) introduced the acquisition of the emblems Progynova and CycloProgynova and associated property in India from Mercury Pharma Group Ltd.
The deal was executed for $32.15 million. The acquisition is home and doesn’t contain any associated get together transactions, as Mercury Pharma Group will not be linked to Dr Reddy’s or its promoter/promoter group firms.
Underneath the settlement, Dr Reddy’s has obtained the rights to those specialty brands for India, strengthening its gynaecology portfolio and marking its entry into the hormone substitute remedy (HRT) section.
Additionally Learn: Dr Reddy’s near Canada approval for generic weight reduction drug: GV Prasad
Progynova (estradiol valerate) is indicated for treating oestrogen deficiency signs and stopping postmenopausal osteoporosis, whereas CycloProgynova (estradiol valerate and norgestrel) offers mixed oestrogen and progestogen remedy for oestrogen deficiency.
Progynova is the No. 1 model within the estradiol represented pharmaceutical market in India, with robust doctor fairness and model recall. In line with IQVIA MAT December 2025 knowledge, the model recorded gross sales of ₹100 crore. The acquisition is anticipated to strengthen Dr Reddy’s presence in premium gynaecology therapies in India.
MV Ramana, Chief Govt Officer, Branded Markets (India and Rising Markets), Dr Reddy’s, stated: “The acquisition will function the spearhead of our enlargement into the HRT section, strengthening our current gynaecology portfolio in India. This acquisition brings a primary-in-class remedy nearer to sufferers, underscoring our dedication to innovation and affected person care on the centre of every little thing we do.”
Additionally Learn: Dr Reddy’s Q2 Outcomes | Internet revenue up 7%, income climbs 10% to ₹8,828 crore; beats estimates
Shares of Dr Reddy’s Laboratories Ltd ended at ₹1,283, down by ₹2, or 0.16%, on the BSE at this time, February 18.
Source link
#Reddys #boosts #gynaecology #portfolio #acquires #HRT #brands #Mercury #Pharma #CNBC #TV18
